LGALS3 and diabetes mellitus: Galectin-3 was shown to be a potential biomarker for the following outcomes: HF in patients with type 2 diabetes mellitus [106], LV remodeling in patients with anterior-wall MI treated by primary PCI [107], and composite CV death and HF hospitalization at 1 year in patients with first-time STEMI treated by primary PCI [21].